BioHive Utah · Jun 2026
BioHive Utah highlighted Eris Biotech as the 2026 Women in Tech & Science Award winner and noted it was co-founded by Evita Weagel and Rachel Brog Garlick.
Our drugs engage the immune system to fight tumors
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Eris Biotech is a Utah-based biotechnology research startup developing oral small-molecule cancer therapeutics that block tumor immune evasion and aim to reawaken the immune system, starting with mesothelioma.
Primary product
Oral small-molecule immuno-oncology therapy platform / hypoxia-activated prodrugs for solid tumors
Founded
2023
Headquarters
Lehi, Utah, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Oncology / immuno-oncology
Offices
American Fork, Utah, United States
Business model
therapeutic development
biopharma
Funding
People & investors
Work & culture
Mission-driven, patient-centered biotech focused on safer cancer treatments with lower systemic toxicity; public benefits details were not found.
Product & market
Differentiators
- —Tumor-local activation under hypoxic conditions
- —Oral small-molecule format
- —Not dependent on a single protein target
- —Designed to reduce systemic toxicity
- —Targets immune evasion rather than directly poisoning tumors
Technology
small molecules
hypoxia-activated prodrugs (HAPs)
tumor-local activation chemistry
oral drug delivery
immune evasion pathway inhibition
Competitors
Jazz Pharmaceuticals
Sana Biotechnology
Senti Bio
BeiGene
X4 Pharmaceuticals
Scale & contact
Estimated revenue
Less than $1M
Estimated monthly visits
397
Traffic estimate as of Jun 2026
Latest news
Eris Biotech / LinkedIn · Oct 2025
Eris Biotech announced that CEO Evita Weagel was recognized with the Women’s Tech Award for biotech disruption.
Eris Biotech / LinkedIn · Aug 2025
The company announced selection into MSK’s 2025 Therapeutics Accelerator, highlighting collaboration with MSK scientists and commercialization experts on its oral small-molecule therapy.
BioUtah · Feb 2024
BioUtah announced Eris Biotech’s acceptance into Y Combinator and summarized the company’s hypoxia-activated prodrug approach for solid tumors and mesothelioma.
Y Combinator · Feb 2024
YC introduced Eris Biotech’s launch, explaining its hypoxia-activated prodrug approach, tumor-local drug activation, and mesothelioma lead program.
Jobs and careers at Eris Biotech
0 jobs at Eris Biotech
No open positions
Check back later for new openings